



INTEGRATED PROTEINS LIMITED

City Point, 5th Floor, Opp. Town Hall, Jamnagar – 361 001, Gujarat, India

Phone: (0288) 2551901 Fax: (0288) 2552566

Email ID: ipl.complianceofficer@gmail.com

Website: www.integratedproteins.com

CIN: L62013GJ1992PLC018426

Date: 14th August, 2025

To,

BSE Limited

Corporate Relationship Department

1st Floor, New Trading Ring,

PJ Tower, Dalal Street,

Fort, Mumbai- 400 001,

Maharashtra, India.

Sub: Outcome of Board Meeting pursuant to Regulation 30, 32 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI LODR”).

Scrip Code - 519606

Respected Sir / Madam,

Pursuant to the provisions of Regulation 30 (read with Part A of Schedule III) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), and in continuation to our letter dated 8th August, 2025, we hereby report the outcome of the meeting of the Board of Directors held today, i.e. Thursday, 14th August, 2025, inter-alia, to consider and approve the following:

1. Considered and approved the unaudited financial results for the quarter ended 30th June, 2025 together with the Limited Review Report by the Auditors.

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We hereby confirm that there has been no deviation or variation in the use of proceeds from the purposes stated in Annexure-A.

The Board meeting commenced at 02:00 PM and ended at 2:30 P.M. You are requested to take above on your records.

Thanking you in anticipation.

FOR, INTEGRATED PROTEINS LIMITED


KARANJ DHARMESHBHAI DOSHI

MANAGING DIRECTOR

DIN: 10848249

Encl:

1. Unaudited Standalone Statement of Financial Results for the Quarter Ended 30-06-2025
2. Independent Auditor's Review Report
3. Annexure - A



INTEGRATED PROTEINS LIMITED

City Point, 5th Floor, Opp. Town Hall, Jamnagar – 361 001, Gujarat, India

Phone: (0288) 2551901 Fax: (0288) 2552566

Email ID: ipl.complianceofficer@gmail.com

Website: www.integratedproteins.com


CIN: L62013GJ1992PLC018426

Unaudited Standalone Statement of Financial Results for the Quarter Ended 30-06-2025

(Rs. In Lakh except per share data)

Particulars		Quarter Ended			Year Ended
		30-06-2025	31-03-2025	30-06-2024	31-03-2025
A	Date of start of reporting period	01-04-2025	01-01-2025	01-04-2024	01-04-2024
B	Date of end of reporting period	30-06-2025	31-03-2025	30-06-2024	31-03-2025
C	Whether results are audited or unaudited	Unaudited	Audited	Unaudited	Audited
Part I					
I	Revenue From Operations				
	Net sales or Revenue from Operations	-	2,148.67	-	2,149.63
II	Other Income	4.72	3.89	4.02	23.74
III	Total Income (I + II)	4.72	2,152.55	4.02	2,173.36
IV	Expenses				
(a)	Cost of materials consumed	-	-	-	-
(b)	Purchases of stock-in-trade	-	2,102.50	-	2,102.50
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
(d)	Employee benefit expense	0.68	-	0.63	1.63
(e)	Finance Costs	-	-	-	-
(f)	Depreciation and amortisation expense	-	-	0.48	0.96
(g)	Other Expenses	4.04	22.65	3.08	36.33
	Total expenses	4.71	2,125.15	4.19	2,141.42
V	Profit (loss) before Exceptional and Extraordinary Items and tax (III-IV)	0.01	27.40	(0.17)	31.94
VI	Exceptional items				
VIII	Profit (loss) before Tax (V-VI)	0.01	27.40	(0.17)	31.94
X	Tax Expense				
(a)	Current Tax	0.00	6.90	-	8.04
	(Less):- MAT Credit	-	-	-	-
	Current Tax Expense Relating to Prior years	-	-	-	-
(b)	Deferred Tax (Asset)/Liabilities		(0.79)	(0.10)	(1.10)





INTEGRATED PROTEINS LIMITED

City Point, 5th Floor, Opp. Town Hall, Jamnagar – 361 001, Gujarat, India

Phone: (0288) 2551901 Fax: (0288) 2552566

Email ID: ipl.complianceofficer@gmail.com

Website: www.integratedproteins.com

CIN: L62013GJ1992PLC018426

XI	Net Profit/Loss for the period from Continuing Operations (IX-X)	0.01	21.29	(0.07)	25.00
XII	Profit (Loss) from Discontinuing Operaitons	-	-	-	-
XIII	Tax Expenses of Discontinuing Operations	-	-	-	-
XIV	Net Profit (Loss) from Discontinuing Operartions after tax (XII-XIII)	-	-	-	-
XV	Profit (Loss) for the period (XI+XIV)	0.01	21.29	(0.07)	25.00
XVI	Other Comprehensive Income				
	a . i). Amount of item that will not be reclassified to profit or loss	-	-	-	-
	ii). Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	b i). Item that will be reclassified to profit or loss	-	-	-	-
	ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XVII	Total Comprehensive income	0.00	0.00	0.00	0.00
	Total Comprehensive income [Comprising Profit for the Period (After tax) and Other comprehensive income] (XV+XVII)	0.01	21.29	(0.07)	25.00
XVIII	Details of equity share capital				
	Paid-up equity share capital (Face Value of Rs. 10/- per equity share)	352.02	352.02	352.02	352.02
	Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
	Other Equity				
XIX	Earnings per share (Not Annualized for Year ended)	0.00	0.60	(0.00)	0.71
(a)	Earnings per share Continuing Operation (Not Annualised for Year ended)				
	Basic earnings per share before extraordinary items	0.00	0.60	(0.00)	0.71





INTEGRATED PROTEINS LIMITED

City Point, 5th Floor, Opp. Town Hall, Jamnagar – 361 001, Gujarat, India

Phone: (0288) 2551901 Fax: (0288) 2552566

Email ID: ipl.complianceofficer@gmail.com

Website: www.integratedproteins.com

CIN: L62013GJ1992PLC018426

	Diluted earnings per share before extraordinary items	0.00	0.60	(0.00)	0.71
(b)	Earnings per share Discontinuing Operation (Not Annualised for Year ended)				
	Basic earnings per share after extraordinary items	0.00	0.00	0.00	0.00
	Diluted earnings per share after extraordinary items	0.00	0.00	0.00	0.00
(c)	Earnings per share (Not Annualised for Year ended)				
	Basic earnings per share before extraordinary items	0.00	0.60	(0.00)	0.71
	Diluted earnings per share before extraordinary items	0.00	0.60	(0.00)	0.71

Notes:-

Notes to Unaudited Standalone financials results for the quarter ended 30th June 2025:


1	The unaudited standalone financial results are prepared in accordance with the Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, and Companies (Indian Accounting Standards Amendment Rules 2016.
2	The figures for the corresponding previous period have been regrouped/reclassified wherever necessary to make them comparable.
3	The Audit Committee has reviewed the above results and the Board of Directors has approved the above results and its release at their respective meetings held on 14th August , 2025
4	The Company has single reportable business segment. Hence, no separate information for segment wise disclosure is given in accordance with the requirements of Indian Accounting Standard (Ind AS) 108 - "Operating Segments".

Date – 14th August, 2025

Place - Jamnagar

FOR- INTEGRATED PROTEINS LIMITED




KARANJ DOSHI
MANAGING DIRECTOR
DIN: 10848249



Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (as amended)

**To The Board of Directors of
Integrated Proteins Limited**


We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Integrated Proteins Limited** ("the Company") for the quarter ended 30th June 2025 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended.

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors at their meeting held on **14th August 2025**, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" (Ind AS 34), as prescribed under section 133 of the Companies Act, 2013 as amended, read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review of the Statement conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For B B Gusani & Associates
Chartered Accountants**


Bhargav B Gusani
Proprietor
Membership No. 120710
UDIN:
Date: 14th August 2025
Place: Jamnagar





INTEGRATED PROTEINS LIMITED

City Point, 5th Floor, Opp. Town Hall, Jamnagar – 361 001, Gujarat, India

Phone: (0288) 2551901 Fax: (0288) 2552566

Email ID: ipl.complianceofficer@gmail.com

Website: www.integratedproteins.com

CIN: L62013GJ1992PLC018426

ANNEXURE -A

Statement on deviation / variation in utilization of funds raised							
Name of listed entity		Integrated Proteins Limited					
Mode of Fund Raising		Public Issues / Rights Issues / Preferential Issues / QIP / Others		Preferential Issue			
Date of Raising Funds		24/01/2025, 28/01/2025, 01/02/2025, 03/02/2025 & 04/02/2025					
Amount Raised		Rs. 1744.88/- (In Lakhs)					
Report filed for Quarter ended		June-25					
Monitoring Agency		applicable / not applicable		N.A.			
Monitoring Agency Name, if applicable		N.A.					
Is there a Deviation / Variation in use of funds raised		Yes / No		No			
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders		N.A.					
If Yes, Date of shareholder Approval		N.A.					
Explanation for the Deviation / Variation		N.A.					
Comments of the Audit Committee after review		N.A.					
Comments of the auditors, if any							
Objects for which funds have been raised and where there has been a deviation, in the following table							
Original Object		Modified Object, if any	Original Allocation (In Lakhs)	Modified allocation if any	Funds Utilized (In lakhs)	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
The proceeds of the Preferential Issue shall be utilized for capital expenditure, acquisition in the same line of business, repayment of borrowings of the Company, expansion plans including investments in subsidiaries Postal Ballot Notice 20 working capital requirement, exploring new initiatives, meeting future funding requirements, general corporate purposes and such other purpose as the Board may decide.		N.A.	1)Rs.1058.50 for capital expenditure 2)Rs. 667.38 For exploring new initiatives.	N.A.	Rs. 1725.88	N.A.	
Deviation or variation could mean: (a) Deviation in the objects or purposes for which the funds have been raised or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or (c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.							
FOR INTEGRATED PROTEINS LIMITED KARANJ DHARMESHBHAI DOSHI MANAGING DIRECTOR DIN: 10848249 Digitally signed by KARANJ DHARMESHBHAI DOSHI Date: 2025.08.14 14:32:11 +05'30'							